Positive Sentiment: Adjusted EBITDA margin expanded to 23%, adjusted EPS increased to $0.22, and the company repaid $24 million of debt during the quarter. Adjusted EPS increased to $0.22 from $0.21, meeting analyst expectations, while adjusted EBITDA rose 4% to $35.3 million. Adjusted EPS increased to $0.22 from $0.21, meeting analyst expectations, while adjusted EBITDA rose 4% to $35.3 million. Bioventus 2026 second-quarter results presentationManagement reaffirmed 2026 revenue guidance of $600 million to $610 million, adjusted EPS of $0.75 to $0.79, and operating cash flow of $84 million to $89 million. Bioventus Company Profile(Get Free Report)Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions.